Eli Lilly (the manufacturer of Mounjaro / tirzepatide) has announced a UK list-price increase from 1 September 2025 to bring pricing in line with other European countries. While the medicine itself is unchanged, this will affect what all private providers charge. ReutersThe Guardian
What’s changing
-
The increase applies across all doses (2.5 mg to 15 mg) and will affect any private purchase (pharmacies, clinics, and digital providers). Reuters
-
No clinical changes: formulation, strengths and safety profile remain the same. Reuters
-
The decision is the manufacturer’s, not individual providers. Reuters
Our plan at Chiltern Private
-
We are reviewing stock and pricing now; unavoidable increases will only be passed on where required.
-
To help you avoid losing momentum and so you don’t miss out on support during this change, we’re offering:
-
Complimentary telephone review (Power Doctor value-add) to check your current dose and regimen, adherence, side-effects and discuss alternatives if needed.
-
Complimentary in-clinic NAD+ injection at that review visit (subject to clinical suitability).
-
-
If you have a refill due before 1 September, we’ll confirm current pricing and availability at booking.
Considering alternatives?
-
For some patients, Wegovy (semaglutide) may be the more affordable option after 1 September. Wegovy is also MHRA-licensed in the UK to reduce the risk of major cardiovascular events in adults with obesity and established heart disease (we do not prescribe for that indication in weight-management clinics, but the label change reflects additional benefits). GOV.UKThe Pharmaceutical Journal
-
A higher-dose Wegovy (7.2 mg) is not yet available, but 2025 trial data (STEP UP) reported ~20–21% average weight loss vs 17–18% with 2.4 mg. Availability and timing in the UK remain subject to regulatory decisions. GlobeNewswireApplied Clinical Trials
To book your complimentary telephone review, reply to this email or call [phone]. We’ll tailor advice to your treatment history and goals.
Warm regards,
Dr Nishel Patel
Medical Director, Chiltern Private
admin@chilternprivate.com | www.chilternprivate.co.uk
Please don’t change your dose or schedule without medical advice. NAD+ may not suit everyone; we’ll assess suitability at review.